BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kamboj M, Khosa P, Kaltsas A, Babady NE, Son C, Sepkowitz KA. Relapse versus reinfection: surveillance of Clostridium difficile infection. Clin Infect Dis 2011;53:1003-6. [PMID: 21976462 DOI: 10.1093/cid/cir643] [Cited by in Crossref: 62] [Cited by in F6Publishing: 61] [Article Influence: 5.6] [Reference Citation Analysis]
Number Citing Articles
1 Ollech JE, Shen NT, Crawford CV, Ringel Y. Use of probiotics in prevention and treatment of patients with Clostridium difficile infection. Best Pract Res Clin Gastroenterol 2016;30:111-8. [PMID: 27048902 DOI: 10.1016/j.bpg.2016.01.002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
2 Chen Y, Rashid MU, Huang H, Fang H, Nord CE, Wang M, Weintraub A. Molecular characteristics of Clostridium difficile strains from patients with a first recurrence more than 8 weeks after the primary infection. J Microbiol Immunol Infect 2017;50:532-6. [PMID: 26698688 DOI: 10.1016/j.jmii.2015.10.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
3 Seekatz AM, Wolfrum E, DeWald CM, Putler RKB, Vendrov KC, Rao K, Young VB. Presence of multiple Clostridium difficile strains at primary infection is associated with development of recurrent disease. Anaerobe 2018;53:74-81. [PMID: 29859301 DOI: 10.1016/j.anaerobe.2018.05.017] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
4 AbdelKhalek A, Abutaleb NS, Mohammad H, Seleem MN. Antibacterial and antivirulence activities of auranofin against Clostridium difficile. Int J Antimicrob Agents 2019;53:54-62. [PMID: 30273668 DOI: 10.1016/j.ijantimicag.2018.09.018] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 8.8] [Reference Citation Analysis]
5 Kociolek LK, Patel SJ, Shulman ST, Gerding DN. Molecular epidemiology of Clostridium difficile infections in children: a retrospective cohort study. Infect Control Hosp Epidemiol. 2015;36:445-451. [PMID: 25782900 DOI: 10.1017/ice.2014.89] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
6 Barkin JA, Sussman DA, Fifadara N, Barkin JS. Clostridium difficile Infection and Patient-Specific Antimicrobial Resistance Testing Reveals a High Metronidazole Resistance Rate. Dig Dis Sci 2017;62:1035-42. [DOI: 10.1007/s10620-017-4462-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
7 Jasiak NM, Alaniz C, Rao K, Veltman K, Nagel JL. Recurrent Clostridium difficile infection in intensive care unit patients. Am J Infect Control 2016;44:36-40. [PMID: 26432184 DOI: 10.1016/j.ajic.2015.08.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
8 Sammons JS, Toltzis P. Recent trends in the epidemiology and treatment of C. difficile infection in children. Curr Opin Pediatr 2013;25:116-21. [PMID: 23241874 DOI: 10.1097/MOP.0b013e32835bf6c0] [Cited by in Crossref: 25] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
9 Durovic A, Widmer AF, Frei R, Tschudin-Sutter S. Distinguishing Clostridium difficile Recurrence From Reinfection: Independent Validation of Current Recommendations. Infect Control Hosp Epidemiol 2017;38:891-6. [PMID: 28592348 DOI: 10.1017/ice.2017.119] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
10 Ofosu A. Clostridium difficile infection: a review of current and emerging therapies. Ann Gastroenterol 2016;29:147-54. [PMID: 27065726 DOI: 10.20524/aog.2016.0006] [Cited by in Crossref: 61] [Cited by in F6Publishing: 55] [Article Influence: 10.2] [Reference Citation Analysis]
11 Wang MS, Evans CT, Rodriguez T, Gerding DN, Johnson S. Clostridium difficile infection and limitations of markers for severity in patients with hematologic malignancy. Infect Control Hosp Epidemiol. 2013;34:127-132. [PMID: 23295558 DOI: 10.1086/669081] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
12 Shin JH, Warren CA. Prevention and treatment of recurrent Clostridioides difficile infection. Curr Opin Infect Dis 2019;32:482-9. [PMID: 31369420 DOI: 10.1097/QCO.0000000000000587] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
13 Song L, Zhao M, Duffy DC, Hansen J, Shields K, Wungjiranirun M, Chen X, Xu H, Leffler DA, Sambol SP, Gerding DN, Kelly CP, Pollock NR. Development and Validation of Digital Enzyme-Linked Immunosorbent Assays for Ultrasensitive Detection and Quantification of Clostridium difficile Toxins in Stool. J Clin Microbiol 2015;53:3204-12. [PMID: 26202120 DOI: 10.1128/JCM.01334-15] [Cited by in Crossref: 34] [Cited by in F6Publishing: 18] [Article Influence: 4.9] [Reference Citation Analysis]
14 Sun J, Mc Millen T, Babady NE, Kamboj M. Role of Coinfecting Strains in Recurrent Clostridium difficile Infection. Infect Control Hosp Epidemiol 2016;37:1481-4. [PMID: 27572118 DOI: 10.1017/ice.2016.187] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
15 Knight EM, Schiller DS, Fulman MK, Rastogi R. Long-Term Efficacy of Oral Vancomycin Prophylaxis for the Prevention of Clostridium difficile Recurrence. J Pharm Pract 2020;33:633-9. [PMID: 30744479 DOI: 10.1177/0897190019825994] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
16 Kim J. Editorial Commentary: Clostridium difficile in Pediatric Oncology Patients: More Questions Than Answers. Clinical Infectious Diseases 2014;59:404-5. [DOI: 10.1093/cid/ciu308] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
17 Vandell AG, Inoue S, Dennie J, Nagasawa Y, Gajee R, Pav J, Zhang G, Zamora C, Masuda N, Senaldi G. Phase 1 Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Oral Doses of DS-2969b, a Novel GyrB Inhibitor, in Healthy Subjects. Antimicrob Agents Chemother 2018;62:e02537-17. [PMID: 29439973 DOI: 10.1128/AAC.02537-17] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
18 Dayananda P, Wilcox MH. A Review of Mixed Strain Clostridium difficile Colonization and Infection. Front Microbiol 2019;10:692. [PMID: 31024483 DOI: 10.3389/fmicb.2019.00692] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
19 Álvarez-hernández D, González-chávez A, González-hermosillo-cornejo D, Franyuti-kelly G, Díaz-girón-gidi A, Vázquez-lópez R. Present and past perspectives on Clostridium difficile infection. Revista de Gastroenterología de México (English Edition) 2018;83:41-50. [DOI: 10.1016/j.rgmxen.2017.07.016] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
20 Shaughnessy MK, Bobr A, Kuskowski MA, Johnston BD, Sadowsky MJ, Khoruts A, Johnson JR. Environmental Contamination in Households of Patients with Recurrent Clostridium difficile Infection. Appl Environ Microbiol 2016;82:2686-92. [PMID: 26921425 DOI: 10.1128/AEM.03888-15] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 3.7] [Reference Citation Analysis]
21 Trindade C, Domingues RMC, Ferreira E. The epidemiology of Clostridioides difficile infection in Brazil: A systematic review covering thirty years. Anaerobe 2019;58:13-21. [DOI: 10.1016/j.anaerobe.2019.03.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
22 Peterfreund GL, Vandivier LE, Sinha R, Marozsan AJ, Olson WC, Zhu J, Bushman FD. Succession in the gut microbiome following antibiotic and antibody therapies for Clostridium difficile. PLoS One 2012;7:e46966. [PMID: 23071679 DOI: 10.1371/journal.pone.0046966] [Cited by in Crossref: 64] [Cited by in F6Publishing: 53] [Article Influence: 6.4] [Reference Citation Analysis]
23 Mathur T, Barman TK, Kumar M, Singh D, Kumar R, Khera MK, Yamada M, Inoue SI, Upadhyay DJ, Masuda N. In Vitro and In Vivo Activities of DS-2969b, a Novel GyrB Inhibitor, against Clostridium difficile. Antimicrob Agents Chemother 2018;62:e02157-17. [PMID: 29439962 DOI: 10.1128/AAC.02157-17] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
24 AbdelKhalek A, Ashby CR Jr, Patel BA, Talele TT, Seleem MN. In Vitro Antibacterial Activity of Rhodanine Derivatives against Pathogenic Clinical Isolates. PLoS One 2016;11:e0164227. [PMID: 27711156 DOI: 10.1371/journal.pone.0164227] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
25 Gutiérrez RL, Riddle MS, Porter CK. Epidemiology of Clostridium difficile infection among active duty United States military personnel (1998-2010). BMC Infect Dis 2013;13:609. [PMID: 24373384 DOI: 10.1186/1471-2334-13-609] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
26 Mendelsohn RB, Kaltsas A, King S, Hwang C, Kassam Z, Abend AM, Kramer E, Kamboj M. Fecal Microbiota Transplantation Is Safe for Clostridiodies difficile Infection in Patients with Solid Tumors Undergoing Chemotherapy. Dig Dis Sci 2021. [PMID: 34089134 DOI: 10.1007/s10620-021-07024-z] [Reference Citation Analysis]
27 Lavergne V, Beauséjour Y, Pichette G, Ghannoum M, Su SH. Lymphopenia as a novel marker of Clostridium difficile infection recurrence. Journal of Infection 2013;66:129-35. [DOI: 10.1016/j.jinf.2012.11.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
28 Jones AM, Kuijper EJ, Wilcox MH. Clostridium difficile: a European perspective. J Infect. 2013;66:115-128. [PMID: 23103666 DOI: 10.1016/j.jinf.2012.10.019] [Cited by in Crossref: 85] [Cited by in F6Publishing: 79] [Article Influence: 8.5] [Reference Citation Analysis]
29 Collins J, Auchtung JM. Control of Clostridium difficile Infection by Defined Microbial Communities. Microbiol Spectr 2017;5. [PMID: 28936948 DOI: 10.1128/microbiolspec.BAD-0009-2016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
30 Garneau JR, Valiquette L, Fortier LC. Prevention of Clostridium difficile spore formation by sub-inhibitory concentrations of tigecycline and piperacillin/tazobactam. BMC Infect Dis 2014;14:29. [PMID: 24422950 DOI: 10.1186/1471-2334-14-29] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 4.6] [Reference Citation Analysis]
31 García-Fernández S, Frentrup M, Steglich M, Gonzaga A, Cobo M, López-Fresneña N, Cobo J, Morosini MI, Cantón R, Del Campo R, Nübel U. Whole-genome sequencing reveals nosocomial Clostridioides difficile transmission and a previously unsuspected epidemic scenario. Sci Rep 2019;9:6959. [PMID: 31061423 DOI: 10.1038/s41598-019-43464-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
32 Taori SK, Wroe A, Poxton IR. Clostridium difficile infections in South East Scotland: mortality and recurrence in a region without PCR ribotype 027. Journal of Medical Microbiology 2013;62:1468-77. [DOI: 10.1099/jmm.0.061093-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
33 Mccollum DL, Rodriguez JM. Detection, Treatment, and Prevention of Clostridium difficile Infection. Clinical Gastroenterology and Hepatology 2012;10:581-92. [DOI: 10.1016/j.cgh.2012.03.008] [Cited by in Crossref: 46] [Cited by in F6Publishing: 34] [Article Influence: 4.6] [Reference Citation Analysis]
34 Locher HH, Seiler P, Chen X, Schroeder S, Pfaff P, Enderlin M, Klenk A, Fournier E, Hubschwerlen C, Ritz D. In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections. Antimicrob Agents Chemother. 2014;58:892-900. [PMID: 24277020 DOI: 10.1128/aac.01830-13] [Cited by in Crossref: 66] [Cited by in F6Publishing: 36] [Article Influence: 7.3] [Reference Citation Analysis]
35 van Kleef E, Gasparrini A, Guy R, Cookson B, Hope R, Jit M, Robotham JV, Deeny SR, Edmunds WJ. Nosocomial transmission of C. difficile in English hospitals from patients with symptomatic infection. PLoS One 2014;9:e99860. [PMID: 24932484 DOI: 10.1371/journal.pone.0099860] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
36 Gupta SB, Dubberke ER. Overview and changing epidemiology of Clostridium difficile infection. Seminars in Colon and Rectal Surgery 2014;25:118-23. [DOI: 10.1053/j.scrs.2014.05.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
37 Green DA, Stotler B, Jackman D, Whittier S, Della-Latta P. Clinical characteristics of patients who test positive for Clostridium difficile by repeat PCR. J Clin Microbiol. 2014;52:3853-3855. [PMID: 25122866 DOI: 10.1128/jcm.01659-14] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
38 Marsh JW, Arora R, Schlackman JL, Shutt KA, Curry SR, Harrison LH. Association of relapse of Clostridium difficile disease with BI/NAP1/027. J Clin Microbiol 2012;50:4078-82. [PMID: 23052318 DOI: 10.1128/JCM.02291-12] [Cited by in Crossref: 90] [Cited by in F6Publishing: 52] [Article Influence: 9.0] [Reference Citation Analysis]
39 Gómez S, Chaves F, Orellana MA. Clinical, epidemiological and microbiological characteristics of relapse and re-infection in Clostridium difficile infection. Anaerobe 2017;48:147-51. [PMID: 28830842 DOI: 10.1016/j.anaerobe.2017.08.012] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
40 Delaney MB. Kick the Bucket: One Hospital System’s Journey to Reduce Clostridium Difficile. Journal of Emergency Nursing 2017;43:519-25. [DOI: 10.1016/j.jen.2017.02.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
41 Clayton JA, Toltzis P. Recent Issues in Pediatric Clostridium difficile Infection. Curr Infect Dis Rep 2017;19:49. [PMID: 29110105 DOI: 10.1007/s11908-017-0603-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
42 Scappaticci GB, Perissinotti AJ, Nagel JL, Bixby DL, Marini BL. Risk factors and impact of Clostridium difficile recurrence on haematology patients. Journal of Antimicrobial Chemotherapy 2017;72:1488-95. [DOI: 10.1093/jac/dkx005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
43 Price V, Portwine C, Zelcer S, Ethier M, Gillmeister B, Silva M, Schindera C, Yanofsky R, Mitchell D, Johnston DL, Lewis V, Dix D, Cellot S, Michon B, Bowes L, Stobart K, Brossard J, Beyene J, Sung L. Clostridium difficile Infection in Pediatric Acute Myeloid Leukemia: From The Canadian Infections in Acute Myeloid Leukemia Research Group. Pediatric Infectious Disease Journal 2013;32:610-3. [DOI: 10.1097/inf.0b013e31828690a4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
44 Murray B, Wolfe C, Marra A, Pillar C, Shinabarger D. In vitro activity of the novel antibacterial agent ibezapolstat (ACX-362E) against Clostridioides difficile. J Antimicrob Chemother 2020;75:2149-55. [PMID: 32285102 DOI: 10.1093/jac/dkaa134] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
45 Johnson S, Gerding DN, Louie TJ, Ruiz NM, Gorbach SL. Sustained clinical response as an endpoint in treatment trials of Clostridium difficile-associated diarrhea. Antimicrob Agents Chemother 2012;56:4043-5. [PMID: 22615287 DOI: 10.1128/AAC.00605-12] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
46 Singh T, Bedi P, Bumrah K, Singh J, Rai M, Seelam S. Updates in Treatment of Recurrent Clostridium difficile Infection. J Clin Med Res. 2019;11:465-471. [PMID: 31236163 DOI: 10.14740/jocmr3854] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
47 Chilton C, Pickering D, Freeman J. Microbiologic factors affecting Clostridium difficile recurrence. Clinical Microbiology and Infection 2018;24:476-82. [DOI: 10.1016/j.cmi.2017.11.017] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
48 Kraus CN, Lyerly MW, Carman RJ. Ambush of Clostridium difficile spores by ramoplanin: activity in an in vitro model. Antimicrob Agents Chemother 2015;59:2525-30. [PMID: 25691641 DOI: 10.1128/AAC.04853-14] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
49 Saha S, Yadav D, Pardi R, Patel R, Khanna S, Pardi D. Kinetics of polymerase chain reaction positivity in patients with Clostridioides difficile infection. Therap Adv Gastroenterol 2021;14:17562848211050443. [PMID: 34646361 DOI: 10.1177/17562848211050443] [Reference Citation Analysis]
50 Seril DN, Ashburn JH, Lian L, Shen B. Risk factors and management of refractory or recurrent clostridium difficile infection in ileal pouch patients. Inflamm Bowel Dis. 2014;20:2226-2233. [PMID: 25222656 DOI: 10.1097/mib.0000000000000205] [Cited by in Crossref: 27] [Cited by in F6Publishing: 11] [Article Influence: 3.9] [Reference Citation Analysis]
51 Kociolek LK, Gerding DN, Osmolski JR, Patel SJ, Snydman DR, McDermott LA, Hecht DW. Differences in the Molecular Epidemiology and Antibiotic Susceptibility of Clostridium difficile Isolates in Pediatric and Adult Patients. Antimicrob Agents Chemother 2016;60:4896-900. [PMID: 27270275 DOI: 10.1128/AAC.00714-16] [Cited by in Crossref: 15] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
52 Nana T, Moore C, Boyles T, Brink AJ, Cleghorn J, Devenish LM, du Toit B, Fredericks ES, Lekalakala-Mokaba MR, Maluleka C, Rajabally MN, Reubenson G, Shuping L, Swart K, Swe Han KS, Wadula J, Wojno J, Lowman W. South African Society of Clinical Microbiology Clostridioides difficile infection diagnosis, management and infection prevention and control guideline. S Afr J Infect Dis 2020;35:219. [PMID: 34485483 DOI: 10.4102/sajid.v35i1.219] [Reference Citation Analysis]
53 Barker A, Duster M, Valentine S, Archbald-Pannone L, Guerrant R, Safdar N. Probiotics for Clostridium difficile infection in adults (PICO): Study protocol for a double-blind, randomized controlled trial. Contemp Clin Trials 2015;44:26-32. [PMID: 26210512 DOI: 10.1016/j.cct.2015.07.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
54 Abutaleb NS, Seleem MN. Repurposing the Antiamoebic Drug Diiodohydroxyquinoline for Treatment of Clostridioides difficile Infections. Antimicrob Agents Chemother 2020;64:e02115-19. [PMID: 32253206 DOI: 10.1128/AAC.02115-19] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
55 Jacobson SM, Slain D. Evaluation of a bedside scoring system for predicting clinical cure and recurrence of Clostridium difficile infections. Am J Health Syst Pharm 2015;72:1871-5. [PMID: 26490821 DOI: 10.2146/ajhp150076] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
56 Alfayyadh M, Collins DA, Tempone S, McCann R, Armstrong PK, Riley TV, Cook A. Recurrence of Clostridium difficile infection in the Western Australian population. Epidemiol Infect 2019;147:e153. [PMID: 31063109 DOI: 10.1017/S0950268819000499] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
57 Mac Aogáin M, Moloney G, Kilkenny S, Kelleher M, Kelleghan M, Boyle B, Rogers TR. Whole-genome sequencing improves discrimination of relapse from reinfection and identifies transmission events among patients with recurrent Clostridium difficile infections. J Hosp Infect 2015;90:108-16. [PMID: 25935700 DOI: 10.1016/j.jhin.2015.01.021] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 4.6] [Reference Citation Analysis]
58 Parmar SR, Bhatt V, Yang J, Zhang Q, Schuster M. A retrospective review of metronidazole and vancomycin in the management of Clostridium difficile infection in patients with hematologic malignancies. J Oncol Pharm Pract 2014;20:172-82. [DOI: 10.1177/1078155213490004] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
59 Herbert R, Hatcher J, Jauneikaite E, Gharbi M, d'Arc S, Obaray N, Rickards T, Rebec M, Blandy O, Hope R, Thomas A, Bamford K, Jepson A, Sriskandan S. Two-year analysis of Clostridium difficile ribotypes associated with increased severity. J Hosp Infect 2019;103:388-94. [PMID: 31220480 DOI: 10.1016/j.jhin.2019.06.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
60 Berkefeld A, Berger FK, Gärtner BC, Wantia N, Prinzing A, Laugwitz KL, Busch DH, Rothe K. Clostridioides (Clostridium) difficile Pacemaker Infection. Open Forum Infect Dis 2020;7:ofaa487. [PMID: 33324719 DOI: 10.1093/ofid/ofaa487] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
61 Álvarez-Hernández DA, González-Chávez AM, González-Hermosillo-Cornejo D, Franyuti-Kelly GA, Díaz-Girón-Gidi A, Vázquez-López R. Present and past perspectives on Clostridium difficile infection. Rev Gastroenterol Mex (Engl Ed) 2018;83:41-50. [PMID: 28684034 DOI: 10.1016/j.rgmx.2017.03.004] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
62 Lavallée C, Labbé AC, Talbot JD, Alonso CD, Marr KA, Cohen S, Laverdière M, Dufresne SF. Risk factors for the development of Clostridium difficile infection in adult allogeneic hematopoietic stem cell transplant recipients: A single-center study in Québec, Canada. Transpl Infect Dis 2017;19. [PMID: 27943498 DOI: 10.1111/tid.12648] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]